BD increases domestic syringe production at Nebraska and Connecticut facilities following FDA safety communication regarding certain plastic syringes; BD reaffirms commitment to upholding product safety and quality

FRANKLIN LAKES, New Jersey , March 21, 2024 (press release) –

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the March 19, 2024 U.S. Food and Drug Administration (FDA) Safety Communication, which provided important updates on FDA's ongoing evaluation of certain plastic syringes:

Eric Borin, president of BD Medication Delivery Solutions said, "BD has the capacity to support additional syringe demand and is further increasing U.S. production to help ensure continuity of patient care. Since the initial FDA safety communication in November, BD has increased domestic manufacturing of syringes in our Nebraska and Connecticut facilities to respond to customer needs.

"Ensuring the safety and quality of our products is the top priority at BD. The latest FDA safety communication does not include any BD syringes. Over our more than 125-year history, we have served the health care system's need for essential high quality medical products, including manufacturing 2 billion additional syringes and needles to support the global pandemic response to COVID-19. BD remains committed to supporting the health care system and patients, and our clinical staff are prepared to support customers with any questions they may have regarding our products."

For more information on BD's commitment to quality, safety and our customers, please visit: https://www.bd.com/en-us/about-bd/quality-at-bd. 

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-increases-domestic-production-to-support-us-health-care-need-for-syringes-302095818.html

SOURCE BD (Becton, Dickinson and Company)

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.